Research progress of Yttrium-90 microsphere selective internal radiation therapy in downstaging and conversion of hepatocellular carcinoma
10.12025/j.issn.1008-6358.2025.20241508
- VernacularTitle:钇-90微球选择性内放射治疗在肝细胞癌降期转化中的研究进展
- Author:
Licong LIANG
1
;
Yuchan LIANG
1
;
Wensou HUANG
1
;
Yongjian GUO
1
;
Jingjun HUANG
1
;
Liteng LIN
1
;
Mingyue CAI
1
;
Kangshun ZHU
1
Author Information
1. Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510245, Guangdong, China.
- Publication Type:Monographicreport:Yttrium-90microsphereinternalradiationtherapyonlivercancer
- Keywords:
hepatocellular carcinoma;
Yttrium-90;
selective internal radiation therapy;
downstaging therapy;
conversion therapy;
bridging therapy
- From:
Chinese Journal of Clinical Medicine
2025;32(1):9-14
- CountryChina
- Language:Chinese
-
Abstract:
The incidence and mortality of hepatocellular carcinoma (HCC) in China are among the highest in the world, imposing a heavy social burden. Liver resection and liver transplantation are the primary radical treatments for HCC, although most patients are no longer able to meet the surgical requirements at initial diagnosis. Yttrium-90 microsphere selective internal radiation therapy (90Y-SIRT) has the advantages of shrinking tumors, enlarging residual liver, regressing portal vein tumor thrombus and improving the quality of life, which can be used for conversion, downstaging and bridging therapy for HCC before surgical treatment, enabling patients regain the chance of radical treatment and reducing the postoperative recurrence rate. This review focuses on the clinical application and progress of 90Y-SIRT in this field.
